Results 181 to 190 of about 464,776 (390)

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina).

open access: yesCirculation, 2003
R. Gibbons   +20 more
semanticscholar   +1 more source

Machine Learning‐Based Prediction of Life‐Threatening Complications During Hemodialysis in Hospitalized Patients With Poor General Conditions

open access: yesArtificial Organs, EarlyView.
A machine learning model using predialysis data predicted sudden events during or after hemodialysis with high accuracy (auROC: 0.889). The key predictors included emergency hospitalization, recent surgery, high heart rate, low albumin levels, and high CRP.
Naotaka Kato   +11 more
wiley   +1 more source

Ludwig's angina [PDF]

open access: yesBritish Dental Journal, 2020
Miah, M. R., Ali, A. S.
openaire   +2 more sources

ANGINA PECTORIS. [PDF]

open access: bronze, 1903
Lauder Brunton
openalex   +1 more source

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.

open access: yesAmerican Journal of Epidemiology, 1997
S. Manzi   +7 more
semanticscholar   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev   +36 more
wiley   +1 more source

Feasibility of visual aids for risk evaluation by hospitalized patients with coronary artery disease: results from face-to-face interviews

open access: yesPatient Preference and Adherence, 2018
Carlos Alberto da Silva Magliano,1 Andrea Liborio Monteiro,2 Bernardo Rangel Tura,1 Claudia Silvia Rocha Oliveira,1 Amanda Rebeca de Oliveira Rebelo,1 Claudia Cristina de Aguiar Pereira3 1NATS, Instituto Nacional de Cardiologia, INC, Rio de Janeiro, Rio
Magliano CAS   +5 more
doaj  

<b>Plasma Levels of Oxidized Low Density Lipoprotein Are Associated With Stable Angina Pectoris and Modalities of Acute Coronary Syndrome</b>

open access: bronze, 2008
Michinori Imazu   +10 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy